BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17895481)

  • 1. Interferon at 50: new molecules, new potential, new (and old) questions.
    Langer JA
    Sci STKE; 2007 Sep; 2007(405):pe53. PubMed ID: 17895481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferons, interferon-like cytokines, and their receptors.
    Pestka S; Krause CD; Walter MR
    Immunol Rev; 2004 Dec; 202():8-32. PubMed ID: 15546383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation of the IFNAR-1 receptor binding site of human IFN-alpha2 generates type I IFN competitive antagonists.
    Pan M; Kalie E; Scaglione BJ; Raveche ES; Schreiber G; Langer JA
    Biochemistry; 2008 Nov; 47(46):12018-27. PubMed ID: 18937499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping human interferon-alpha (IFN-alpha 2) binding determinants of the type I interferon receptor subunit IFNAR-1 with human/bovine IFNAR-1 chimeras.
    Goldman LA; Cutrone EC; Dang A; Hao X; Lim JK; Langer JA
    Biochemistry; 1998 Sep; 37(37):13003-10. PubMed ID: 9737881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases.
    Brideau-Andersen AD; Huang X; Sun SC; Chen TT; Stark D; Sas IJ; Zadik L; Dawes GN; Guptill DR; McCord R; Govindarajan S; Roy A; Yang S; Gao J; Chen YH; Skartved NJ; Pedersen AK; Lin D; Locher CP; Rebbapragada I; Jensen AD; Bass SH; Nissen TL; Viswanathan S; Foster GR; Symons JA; Patten PA
    Proc Natl Acad Sci U S A; 2007 May; 104(20):8269-74. PubMed ID: 17494769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human interferons alpha, beta and omega.
    Bekisz J; Schmeisser H; Hernandez J; Goldman ND; Zoon KC
    Growth Factors; 2004 Dec; 22(4):243-51. PubMed ID: 15621727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
    Pfeffer LM; Dinarello CA; Herberman RB; Williams BR; Borden EC; Bordens R; Walter MR; Nagabhushan TL; Trotta PP; Pestka S
    Cancer Res; 1998 Jun; 58(12):2489-99. PubMed ID: 9635566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding and activity of all human alpha interferon subtypes.
    Lavoie TB; Kalie E; Crisafulli-Cabatu S; Abramovich R; DiGioia G; Moolchan K; Pestka S; Schreiber G
    Cytokine; 2011 Nov; 56(2):282-9. PubMed ID: 21856167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human type I interferons: structure and function.
    Kontsek P
    Acta Virol; 1994 Dec; 38(6):345-60. PubMed ID: 7793359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel interferon delta genes in mammals: cloning of one gene from the sheep, two genes expressed by the horse conceptus and discovery of related sequences in several taxa by genomic database screening.
    Cochet M; Vaiman D; Lefèvre F
    Gene; 2009 Mar; 433(1-2):88-99. PubMed ID: 19110041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variations in the unstructured C-terminal tail of interferons contribute to differential receptor binding and biological activity.
    Slutzki M; Jaitin DA; Yehezkel TB; Schreiber G
    J Mol Biol; 2006 Jul; 360(5):1019-30. PubMed ID: 16815442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type III IFNs: new layers of complexity in innate antiviral immunity.
    Ank N; Paludan SR
    Biofactors; 2009; 35(1):82-7. PubMed ID: 19319850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic effects of interferons: relevance to multiple sclerosis.
    Rudick RA; Ransohoff RM
    Mult Scler; 1995; 1 Suppl 1():S12-6. PubMed ID: 9345391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of interferon mediated anti-viral resistance.
    Clarke CJ; Trapani JA; Johnstone RW
    Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):117-30. PubMed ID: 12476793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers.
    Lamken P; Lata S; Gavutis M; Piehler J
    J Mol Biol; 2004 Jul; 341(1):303-18. PubMed ID: 15312780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Historical developments in the research of interferon receptors.
    Krause CD; Pestka S
    Cytokine Growth Factor Rev; 2007; 18(5-6):473-82. PubMed ID: 17693124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense.
    Zhang SY; Boisson-Dupuis S; Chapgier A; Yang K; Bustamante J; Puel A; Picard C; Abel L; Jouanguy E; Casanova JL
    Immunol Rev; 2008 Dec; 226():29-40. PubMed ID: 19161414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human interferon system: characterization and classification after discovery of novel members.
    Kontsek P; Karayianni-Vasconcelos G; Kontseková E
    Acta Virol; 2003; 47(4):201-15. PubMed ID: 15068375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The search for the IFN-gamma receptor in fish: Functional and expression analysis of putative binding and signalling chains in rainbow trout Oncorhynchus mykiss.
    Gao Q; Nie P; Thompson KD; Adams A; Wang T; Secombes CJ; Zou J
    Dev Comp Immunol; 2009 Aug; 33(8):920-31. PubMed ID: 19454334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interference by interferons: Janus faces in vascular proliferative diseases.
    Wessely R
    Cardiovasc Res; 2005 Jun; 66(3):433-43. PubMed ID: 15914108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.